Siegel PM - Search Results

1

PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.

Andrzejewski S, Klimcakova E, Johnson RM, Tabariès S, Annis MG, McGuirk S, Northey JJ, Chénard V, Sriram U, Papadopoli DJ, Siegel PM, St-Pierre J. Andrzejewski S, et al. Among authors: siegel pm. Cell Metab. 2017 Nov 7;26(5):778-787.e5. doi: 10.1016/j.cmet.2017.09.006. Epub 2017 Oct 5. Cell Metab. 2017. PMID: 28988825 Free article.

2

Targeting aberrant TGF-beta signaling in pre-clinical models of cancer.

Mourskaia AA, Northey JJ, Siegel PM. Mourskaia AA, et al. Among authors: siegel pm. Anticancer Agents Med Chem. 2007 Sep;7(5):504-14. doi: 10.2174/187152007781668689. Anticancer Agents Med Chem. 2007. PMID: 17896911 Review.

3

Osteoactivin promotes breast cancer metastasis to bone.

Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. Rose AA, et al. Among authors: siegel pm. Mol Cancer Res. 2007 Oct;5(10):1001-14. doi: 10.1158/1541-7786.MCR-07-0119. Mol Cancer Res. 2007. PMID: 17951401

4

Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion.

Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM. Northey JJ, et al. Among authors: siegel pm. Mol Cell Biol. 2008 May;28(10):3162-76. doi: 10.1128/MCB.01734-07. Epub 2008 Mar 10. Mol Cell Biol. 2008. PMID: 18332126 Free PMC article.

5

GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis.

Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguère V, Siegel PM, Bouchard M. Dydensborg AB, et al. Among authors: siegel pm. Oncogene. 2009 Jul 23;28(29):2634-42. doi: 10.1038/onc.2009.126. Epub 2009 Jun 1. Oncogene. 2009. PMID: 19483726

6

The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.

Roovers K, Wagner S, Storbeck CJ, O'Reilly P, Lo V, Northey JJ, Chmielecki J, Muller WJ, Siegel PM, Sabourin LA. Roovers K, et al. Among authors: siegel pm. Oncogene. 2009 Aug 6;28(31):2839-48. doi: 10.1038/onc.2009.146. Epub 2009 Jun 15. Oncogene. 2009. PMID: 19525980

7

Emerging therapeutic targets in breast cancer bone metastasis.

Rose AA, Siegel PM. Rose AA, et al. Among authors: siegel pm. Future Oncol. 2010 Jan;6(1):55-74. doi: 10.2217/fon.09.138. Future Oncol. 2010. PMID: 20021209 Free article. Review.

8

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM. Rose AA, et al. Among authors: siegel pm. PLoS One. 2010 Aug 10;5(8):e12093. doi: 10.1371/journal.pone.0012093. PLoS One. 2010. PMID: 20711474 Free PMC article.

9

CdGAP is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion.

He Y, Northey JJ, Primeau M, Machado RD, Trembath R, Siegel PM, Lamarche-Vane N. He Y, et al. Among authors: siegel pm. Oncogene. 2011 Mar 3;30(9):1032-45. doi: 10.1038/onc.2010.477. Epub 2010 Nov 1. Oncogene. 2011. PMID: 21042277

10

Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes.

Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, Hallett M, Siegel PM. Tabariès S, et al. Among authors: siegel pm. Oncogene. 2011 Mar 17;30(11):1318-28. doi: 10.1038/onc.2010.518. Epub 2010 Nov 15. Oncogene. 2011. PMID: 21076473

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

165 results

Search Page